Can Loneliness & Depression Harm Your Heart? Here's What Experts Say

Updated Feb 2, 2025 | 03:00 AM IST

SummarySubtle symptoms of heart disease, such as fatigue, shortness of breath, swelling in the lower legs, dizziness, and jaw pain, are often overlooked. These signs play an important role in the early detection of heart diseases.
Depression and heart health

Depression and heart health (Credit: Canva)

Heart disease is often linked to high cholesterol, obesity, or lack of exercise. However, there is mounting evidence that suggests that mental health plays a crucial role in cardiovascular well-being. Stress, anxiety, and depression can silently strain the heart, increasing the risk of serious complications.

A recent study, published in Nature Human Behaviour, showed that loneliness has a significant impact on proteins present in a person's blood. For the study, researchers used data from more than 42,000 participants to explore whether the 9.3% who reported social isolation and 6.4% who reported loneliness had different levels of proteins in their blood compared with those who did not. The researchers then studied data that tracked the health of participants over an average 14-year period.

"We found around 90% of these proteins are linked to the risk of mortality," Dr Chun Shen, Fudan University in China, who is also the lead researcher said. "In addition, about 50% of the proteins were linked to cardiovascular disease, type 2 diabetes and stroke," he added.

Dr Shrey Kumar Srivastav, senior consultant at Sharda Hospital, said that subtle symptoms of heart disease, such as fatigue, shortness of breath, swelling in the lower legs, dizziness, and jaw pain, are often overlooked or attributed to stress and ageing. "Women, in particular, may experience atypical signs like extreme fatigue, indigestion, or upper abdominal pain instead of classic chest pain, leading to delayed diagnosis," he added.

Can Mental Health Issues Trigger Heart Diseases?

Chronic stress can trigger harmful cardiovascular effects, including elevated blood pressure, increased heart rate, and inflammation—key contributors to heart disease. Anxiety and depression further impact heart health by disrupting sleep patterns, raising stress hormone levels, and encouraging unhealthy habits like poor diet and inactivity.

Mental health issues like depression and anxiety have a profound impact on the heart. They don’t just affect emotions but can increase inflammation and put extra strain on the cardiovascular system, warns Dr Srivastav.

Certain risk factors, such as obesity and diabetes, disproportionately affect women, making them more vulnerable to heart failure with preserved ejection fraction (HFpEF). However, due to gender-specific symptom variations, heart disease in women often goes undiagnosed for longer.

Obesity is more prevalent in women than men and is a major risk factor for heart failure. Diabetes, too, has a greater impact on women’s heart health, yet diagnosis and treatment delays are common. Addressing this gap requires increasing awareness, training healthcare providers, and promoting early diagnostic tools,” explains Dr Srivastav.

How Can You Protect Your Heart?

A simple yet effective way to support heart health is by committing to a brisk 30-minute walk daily. Walking not only helps regulate blood pressure and manage weight but also improves circulation and reduces stress.

"Regular physical activity, paired with a heart-healthy diet rich in fruits, vegetables, whole grains, and lean proteins, significantly lowers cardiovascular risks," advises Dr Srivastav.

Heart disease can often go undetected until a major event occurs, making routine screenings essential.

- For women: Begin screenings around age 30 and continue with regular checkups.

- For men: Start screenings at age 35.

Health screenings, including blood pressure checks, cholesterol tests, and electrocardiograms (ECGs), are critical for early detection of silent heart conditions.

End of Article

US Respiratory Viruses In 2026: CDC Identifies 4 Illnesses To Watch

Updated Nov 19, 2026 | 01:00 AM IST

SummaryThe CDC has reported elevated rhinovirus/enterovirus and respiratory adenovirus activity across the US, with adenovirus increasing in some regions. It has also flagged Group A strep, whooping cough and walking pneumonia.
US Respiratory Viruses In 2026: CDC Identifies 4 Illnesses To Watch

Credit: iStock

The US Centers for Disease Control and Prevention (CDC) has reported elevated activity of multiple respiratory viruses across the country during the 2026–27 winter season, including rhinovirus/enterovirus and respiratory adenovirus.

While respiratory adenovirus infections are increasing in some regions, the agency says the trends are expected.

In its latest update, the CDC also highlighted Group A strep infections, whooping cough and Mycoplasma pneumoniae, the bacteria responsible for walking pneumonia, as other respiratory illnesses circulating in the US.

Rhinovirus, Adenovirus

Rhinovirus/enterovirus and respiratory adenovirus activity are elevated nationally, according to the CDC. Respiratory adenovirus infections are also increasing in some parts of the country.

Both viruses can cause respiratory symptoms such as cough, fever, nasal congestion and shortness of breath. In severe cases, infections may progress to bronchitis or pneumonia.

Rhinoviruses are among the common causes of the common cold and can also trigger asthma attacks. People with asthma, weakened immune systems or other underlying medical conditions may be at higher risk of severe illness.

Respiratory adenoviruses typically cause mild cold- or flu-like symptoms but can also lead to bronchitis, pneumonia, conjunctivitis (pink eye) and gastrointestinal illness. People with weakened immune systems or existing respiratory or cardiac conditions are at greater risk of severe disease. There are no vaccines available to the public for these infections.

Group A Strep Infections

Reports of Group A strep infections increased in the US as children returned to school this fall, before stabilising, the CDC said.

Most reported infections have involved strep throat or scarlet fever.

However, the bacteria can also cause serious conditions, including streptococcal toxic shock syndrome and necrotising fasciitis, commonly known as flesh-eating disease.

Although most infections are minor, serious illness can occur, particularly among older adults and people with certain underlying health conditions. Healthcare providers can diagnose the infection through testing and prescribe antibiotics when needed.

Walking Pneumonia

Respiratory infections caused by Mycoplasma pneumoniae remain low in most parts of the US, based on emergency department visits and positive test results.

The bacteria commonly cause tracheobronchitis, often described as chest colds, but can also lead to walking pneumonia. People of all ages can get infected, although school-aged children and young adults are most commonly affected.

Most mild infections resolve without medication, while healthcare providers may prescribe antibiotics for pneumonia.

Whooping Cough

Whooping cough, or pertussis, continues to circulate at lower levels compared with post-pandemic peaks, according to the CDC.

The highly contagious respiratory infection is caused by the bacterium Bordetella pertussis and can spread easily from person to person.

Babies younger than one year are at the highest risk of severe disease and complications. Vaccination is the best way to prevent complications, and healthcare providers generally treat the infection with antibiotics.

How To Prevent Respiratory Infections

The CDC recommends basic precautions to reduce the spread of respiratory viruses and bacteria, including:

  • Washing hands regularly
  • Cleaning frequently touched surfaces
  • Covering coughs and sneezes
  • Staying home when sick
  • Taking steps to improve indoor air quality.
People with respiratory symptoms such as fever, cough or shortness of breath should take precautions to avoid spreading infections to others. Severe symptoms, particularly difficulty breathing, warrant medical attention.

End of Article

Drug-Resistant TB: 3.7 Lakh Cases Globally In 2025; Less Than Half Started Treatment, Says WHO

Updated Nov 18, 2026 | 10:19 PM IST

SummaryIndia, China and Russia were among the countries contributing substantially to the global RR-TB burden, while India and four others accounted for about 60% of the global treatment gap, according to WHO's Global Tuberculosis Report 2026.
Drug-Resistant TB: 3.7 Lakh Cases Globally In 2025; Less Than Half Started Treatment, Says WHO

Credit: iStock

An estimated 370,000 people developed rifampicin-resistant tuberculosis (RR-TB) worldwide in 2025, highlighting the continuing threat of drug-resistant TB, according to the World Health Organization (WHO).

The Global Tuberculosis Report 2026 showed a gradual decline in RR-TB since 2015. However, major gaps in diagnosis and treatment persist.

Only 155,333 people were diagnosed with RR-TB and started treatment in 2025, just 42% of the estimated number who developed the disease.

Drug-resistant TB occurs when bacteria become resistant to one or more medicines. Rifampicin resistance is particularly concerning because rifampicin is a key first-line TB drug.

India Among Countries Accounting For Over Half Of Global RR-TB Burden

Also read: Global TB Deaths Fall 35% Since 2015, But 2030 Target Remains Distant: WHO

The proportion of new TB cases involving rifampicin resistance fell from 4.4% in 2015 to 3.1% in 2025.

Resistance remained higher among previously treated patients: 14.8% had RR-TB in 2025, down from 20% in 2015.

China, India, the Philippines and the Russian Federation together accounted for more than half of estimated global RR-TB cases in 2025.

Eastern Europe and Central Asia reported the highest proportions of RR-TB among previously treated patients, exceeding 50%.

India was also among five countries — alongside China, Indonesia, Pakistan and the Philippines — that accounted for about 60% of the global gap between estimated RR-TB cases and people enrolled on treatment.

Rifampicin-resistant TB is listed in WHO's Bacterial Priority Pathogens List under the critical group.

Why Is Drug-Resistant TB Concerning?

WHO identifies two main drivers of multidrug- and rifampicin-resistant TB (MDR/RR-TB): inappropriate treatment and person-to-person transmission.

Incorrect use of TB medicines, poor-quality formulations, improper storage and premature treatment stoppage can contribute to drug resistance.

Resistant bacteria can also spread between people. Those with pulmonary TB can transmit the infection through coughing, sneezing or talking. Others become infected by inhaling airborne bacteria.

Timely diagnosis, appropriate treatment and infection prevention are particularly important in crowded settings such as hospitals and prisons.

70% Of Patients With RR-TB Successfully Treated

Read More: 15 Lakh Asymptomatic TB Cases Detected In India: How TB Mukt Bharat Abhiyaan Is Driving Screening

The treatment success rate for RR-TB reached 70% among patients who started treatment in 2023, the latest year with available outcome data.

This was below the 71% recorded in 2022 but above the rates in 2021 (68%), 2020 (64%) and 2012 (50%).

By comparison, treatment success for drug-susceptible TB is about 90%, according to WHO.

Across WHO regions, RR-TB treatment success ranged from 56% in the Region of the Americas to 77% in the African Region.

Six-Month Treatment Regimens Gain Ground

WHO recommends all-oral regimens for drug-resistant TB, including shorter courses for eligible patients. Six-month regimens accounted for 42% of RR-TB treatment in 2025, up from 18% in 2024 and 3% in 2023.

By the end of 2025, 106 countries were using these regimens, compared with 98 in 2024 and 60 in 2023.

They were the most frequently used treatment option in five of the six WHO regions. Uptake was highest in the Eastern Mediterranean (72%) and African (65%) regions.

Europe was the only region where longer regimens remained the main option for a large share of patients (76%).

WHO recommends the six-month BPaLM regimen — bedaquiline, pretomanid, linezolid and moxifloxacin — for eligible patients with MDR/RR-TB.

Treatment choices depend on drug resistance, previous exposure to TB medicines and other clinical factors.

Expanding access to rapid drug-resistance testing, starting treatment promptly and preventing transmission remain key to tackling drug-resistant TB.

End of Article

Experimental Alzheimer's Drug Slows Cognitive Decline By 38% In A Two-Year Trial: How Does It Work?

Updated Nov 18, 2026 | 09:00 PM IST

SummaryBiogen's investigational Alzheimer's drug, injected 60 mg in the spinal cord, showed significant outcomes in slowing down cognitive decline linked with the disease.
Experimental Alzheimer's Drug Slows Cognitive Decline By 38% In A Two-Year Trial: How Does It Work?

Credit: AI image

There are currently no proven treatments to reverse Alzheimer’s but researchers are actively looking into treatments and therapies that could decrease the pace of disease progression and cognitive decline.

An experimental drug may be on the path to achieve that goal after it was able to slow cognitive decline by 38% over two years in people with early-stage Alzheimer’s. The development came to light after new clinical trial findings were announced by pharmaceutical company Biogen.

Experimental Alzheimer's Drug Slows Cognitive Decline

The experimental drug that targets a protein linked to Alzheimer's disease is called diranersen (BIIB080). It is equipped to reduce levels of tau, a protein that accumulates abnormally in the brains of people with Alzheimer's disease and causes damage to nerve cells.

Results from the Phase 2 CELIA trial, presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference, showed that patients receiving the lowest dose of diranersen experienced more cognitive decline at two years than was reported at the 18-month assessment.

The 60 mg dose, administered through an injection into the fluid surrounding the spinal cord twice a year, slowed cognitive decline by 38% on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale at 96 weeks. This was an improvement from the 26% slowing that was observed at 76 weeks.

The two-year results corresponded to a 1.09-point difference on the CDR-SB scale compared to the control group. The scale measures changes in memory, thinking abilities and the ability to do everyday activities.

Also read: 'Viagra For The Brain': New Pill Slows Decline in Memory, Thinking By 31% In Some Alzheimer's Patients

How Does The Investigational Alzheimer's Drug Work?

Tau is a protein that normally helps maintain the structure and stability of nerve cells. But, in Alzheimer's disease, tau can become abnormal, clump together and form structures known as neurofibrillary tangles inside brain cells.

They interfere with the normal functioning of nerve cells and can lead to progressive brain damage, memory loss and cognitive decline, symptoms usually seen in Alzheimer’s patients.

Diranersen belongs to a class of medicines that work by targeting genetic messages involved in producing proteins. In this case, diranersen targets the messenger RNA (mRNA) produced by the MAPT gene, which carries instructions for making tau protein. By targeting this genetic message, the drug aims to reduce the production of tau at source.

Recently approved Alzheimer's treatments like lecanemab and donanemab target amyloid-beta plaques, another abnormal protein accumulation associated with the disease. They work by helping the body clear amyloid deposits from the brain and have demonstrated modest slowing of cognitive decline in people with early Alzheimer's.

Diranersen works differently by targeting tau production rather than amyloid accumulation.

Also read: Older Adults Receiving High-Dose Flu Shots Show Lower Alzheimer's Risk: Study

Side Effects Of Diranersen

Biogen reported that diranersen was well tolerated over the two-year observation period as no new safety concerns came up.

Side effects mostly included headaches and back pain, which could have been due to lumbar puncture procedure used to administer the drug. A small number of participants also experienced confusion.

Unlike some existing Alzheimer's treatments, the trial did not report cases of amyloid-related brain swelling.

Diranersen is still undergoing clinical development and is not approved by the US Food and Drug Administration (FDA) or other regulatory authorities.

End of Article